Publications by authors named "Nikki Ojili"
Article Synopsis
- Chronic obstructive pulmonary disease (COPD) increases the risk of cardiovascular issues, and the ETHOS trial showed that triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF) lowered the rates of exacerbations and all-cause mortality compared to dual therapies.
- The study aimed to evaluate the effects of BGF on cardiovascular events and the time to first severe exacerbation, finding that BGF 320 significantly reduced the occurrence of major adverse cardiac events and other serious cardiopulmonary issues when compared to dual therapy with glycopyrrolate/formoterol fumarate (GFF).
- Overall, BGF demonstrated a notable benefit in reducing